WebDoctor Encyclopedia

Childhood Liver, bile ducts & pancreas Soft-tissue sarcomas

Undifferentiated embryonal sarcoma of the liver (UESL)

Undifferentiated embryonal sarcoma of the liver (UESL) is a rare, fast-growing liver sarcoma that mainly affects children aged 6-10. It often grows very large and looks cystic on scans, but most children are cured with surgery and chemotherapy.

Medically reviewed Last reviewed October 17, 2026

What is undifferentiated embryonal sarcoma of the liver?

Undifferentiated embryonal sarcoma of the liver (UESL) is a rare, fast-growing cancer of the liver that mainly affects school-age children. It arises from primitive connective tissue cells (mesenchymal cells) rather than from liver cells themselves.

After hepatoblastoma and hepatocellular carcinoma, UESL is the third most common liver cancer in children. It accounts for roughly 1 in 10 childhood liver cancers (Putra and Ornvold, 2015).

Most children are between 6 and 10 years old at diagnosis. UESL also occurs in adults, but much less often (Ziogas et al., 2021).

The tumour often becomes very large before it causes symptoms. In the past, the outlook was poor. Today, with complete surgery combined with chemotherapy, most children are cured (Bisogno et al., 2002; Shi et al., 2017).

1. Key facts at a glance

Feature Details
Type of cancer Malignant mesenchymal (sarcoma) tumour of the liver
How common Rare; about 9-15% of childhood liver cancers
Typical age Most 6-10 years; also teenagers and, rarely, adults
Key symptoms Tummy swelling, a lump, pain, fever
Tumour markers AFP is usually normal, unlike hepatoblastoma
Main treatment Complete surgical removal plus chemotherapy
Other options Liver transplant when the tumour cannot be removed
Outlook Good in children with modern treatment: over 8 in 10 survive

2. Causes and risk factors

The cause of UESL is not fully understood. Research has found two important links.

Finding Explanation
Link with mesenchymal hamartoma A benign childhood liver lump; some UESLs seem to arise from it, and both can share changes on chromosome 19q13.4 (Mathews et al., 2013)
TP53 changes Many UESLs carry changes in the TP53 tumour suppressor gene
Complex chromosome changes The tumour cells often have many gains and losses of chromosome material
Inherited risk Not usually inherited; very rare cases occur in families with Li-Fraumeni syndrome

Mesenchymal hamartoma and UESL

Mesenchymal hamartoma is a benign, usually cystic liver lump that mostly appears in babies and toddlers. In a small number of reported cases, UESL has developed in or next to a hamartoma, sometimes years later.

Both tumours can share rearrangements in the same region of chromosome 19, which suggests they may be related conditions at different ends of a spectrum (Mathews et al., 2013). For this reason, doctors usually recommend complete removal of a mesenchymal hamartoma when it is safe, rather than leaving it in place.

UESL is not linked with hepatitis, cirrhosis or alcohol, which cause most adult liver cancers. Nothing a parent did causes it.

3. How does it look

On scans

UESL has a typical and slightly puzzling appearance on imaging.

Feature Description
Size Usually very large, often 10-20 cm
Position Most often in the right lobe of the liver
Ultrasound Looks mostly solid
CT or MRI Looks mostly cystic (fluid-filled), with thin walls and septa
Inside Areas of bleeding and dead tissue; gelatinous (myxoid) material
Spread Lungs, the lining of the abdomen (peritoneum) and nearby tissues

This mismatch between ultrasound and CT happens because the tumour contains a lot of watery, gel-like tissue. Because of the cystic look, UESL can be mistaken for a liver abscess or hydatid cyst, which can delay diagnosis.

To the surgeon

The tumour is usually a large, well-defined mass with a fibrous capsule-like rim. Cut open, it shows soft, glistening, gelatinous tissue mixed with cysts, bleeding and necrosis.

Under the microscope

Feature Description
Cells Spindle-shaped and star-shaped cells in a loose, myxoid background
Giant cells Bizarre, very large cells with several nuclei
Globules Pink droplets in and around cells that stain with PAS and resist diastase
Stains No specific marker; diagnosis relies on the overall pattern and excluding other tumours
Edges Trapped bile ducts and liver cells at the border

Visible signs

Parents usually notice a swollen tummy, often on the right side under the ribs. Some children look thin or pale. Jaundice (yellow skin and eyes) is unusual.

4. Symptoms

Common symptoms

  • Swelling or a lump in the upper abdomen
  • Tummy pain, often dull and persistent
  • Fever without an obvious infection
  • Loss of appetite, nausea and vomiting
  • Weight loss and tiredness
  • Feeling full quickly after small meals

Emergency symptoms

Problem Signs
Tumour rupture or bleeding Sudden severe tummy pain, paleness, fast heartbeat, fainting
Pressure on the lungs Breathlessness from a very large tumour pushing up the diaphragm
Blockage of large veins Swollen legs or tummy (rare)

Rupture can happen spontaneously or after a minor knock and needs emergency surgery.

When to seek medical advice

See a doctor promptly if your child has a swollen tummy, a lump under the ribs, or ongoing pain and fever.

Call emergency services for sudden severe tummy pain, collapse or signs of internal bleeding.

5. Diagnosis

Test Purpose
Ultrasound First scan; shows a large liver mass
CT or MRI of the abdomen Size, cysts, position in relation to blood vessels and bile ducts
CT of the chest Looks for lung spread
Blood tests Liver function, blood count; AFP and other markers are usually normal
Biopsy Confirms the diagnosis; usually a core needle biopsy
Expert pathology review Rare tumour; specialist review is recommended

Staging and risk grouping

UESL is usually assessed with the PRETEXT system, which shows how much of the liver is involved, and with soft-tissue sarcoma staging.

Factor Why it matters
PRETEXT group (I-IV) Shows which parts of the liver are involved and whether surgery is possible
Tumour rupture Raises the risk of spread within the abdomen
Complete versus incomplete removal The most important factor for outcome
Distant spread Uncommon at diagnosis but worsens the outlook

Conditions that can look similar

Condition How it differs
Mesenchymal hamartoma Benign; usually under 2 years; no bizarre cells
Hepatoblastoma Younger children; raised AFP
Hepatocellular carcinoma Older children and adults; often raised AFP
Biliary rhabdomyosarcoma Arises from bile ducts; causes jaundice; muscle markers positive
Liver abscess or hydatid cyst Infection; different blood tests and scan features

6. Treatment

Children with UESL should be treated at a specialist children’s cancer centre with experienced liver surgeons. Treatment usually follows soft-tissue sarcoma protocols (Guerin et al., 2023).

Surgery

Complete removal of the tumour with clear margins is the most important part of treatment.

Situation Approach
Tumour removable at diagnosis Surgery first (partial hepatectomy), then chemotherapy
Very large or close to major vessels Chemotherapy first to shrink it, then surgery
Cannot be removed after chemotherapy Liver transplant in selected children (Walther et al., 2014)
Rupture at diagnosis Emergency surgery to control bleeding, then planned treatment

Chemotherapy often shrinks the solid part of the tumour, making surgery easier and safer.

Chemotherapy

Typical drugs Notes
Ifosfamide, vincristine, actinomycin D Common European sarcoma backbone (IVA)
Doxorubicin Often added (IVADo or VAIA-type regimens)
Cyclophosphamide Used in some North American regimens (VAC)
Duration Usually several months in total

Since chemotherapy became standard alongside surgery, survival has risen sharply from under 40% in older reports to over 80% today (Stocker and Ishak, 1978; Shi et al., 2017).

Radiotherapy

Radiotherapy is not routinely needed. It may be considered when tumour is left behind after surgery or for relapse.

What treatment involves day to day

Treatment usually lasts several months. A central line or port is placed in the chest so that chemotherapy can be given and blood taken without repeated needles.

Part of treatment What families can expect
Chemotherapy cycles Hospital stays of a few days every three weeks or so
Between cycles Low blood counts for a week or two; extra care to avoid infection
Fluids and kidney checks Extra fluids and blood tests with ifosfamide
Heart scans An echocardiogram before and during doxorubicin
Surgery recovery Usually one to two weeks in hospital after major liver surgery
Nutrition Dietitian support, sometimes tube feeding during treatment

UESL in adults

UESL is rare in adults, and most adult cases are reported as single cases or small series. Adults tend to be diagnosed with larger tumours, are less often treated with chemotherapy, and have poorer survival than children in national database studies (Ziogas et al., 2021).

Specialist sarcoma centres usually treat adults with complete surgery and sarcoma-type chemotherapy, similar to the approach used for children. Because the tumour is so rare, adults should ideally be referred to a centre with experience in both liver surgery and sarcoma care.

Why diagnosis can be delayed

Several features make UESL easy to miss at first:

Reason Explanation
Cystic look on CT Can be mistaken for an abscess or a parasitic (hydatid) cyst
Normal AFP The usual liver cancer marker in children does not rise
Few early symptoms The liver can hold a large tumour before it causes pain
Fever Can suggest infection rather than cancer

Draining a suspected abscess that is actually UESL can spread tumour cells, so specialist review of the scans before any drainage is important (Techavichit et al., 2016).

Side effects

Treatment Possible side effects
Liver surgery Bleeding, bile leak, infection; the remaining liver regrows
Chemotherapy Infections, hair loss, sickness, low blood counts
Ifosfamide Kidney effects and possible effects on fertility
Doxorubicin Possible heart damage; heart scans are done
Liver transplant Lifelong medicines to prevent rejection, which increase infection risk

7. Outlook (prognosis)

The outlook for children with UESL is much better than it once was.

Group Approximate outlook
Children, modern treatment About 86% alive at 5 years in a US database (Shi et al., 2017)
Complete resection plus chemotherapy Best results; most children are cured
Incomplete removal or rupture Higher risk of relapse
Liver transplant for unresectable tumours Good long-term survival in published series
Adults Poorer outcomes than children (Ziogas et al., 2021)

Relapses usually happen within the first two years, most often in the liver, abdomen or lungs.

8. Follow-up

Follow-up Purpose
Abdominal ultrasound or MRI Detect local relapse
Chest imaging Detect lung spread
Liver blood tests Check liver function
Heart and kidney checks After doxorubicin and ifosfamide
Growth and development Long-term survivorship care

Follow-up is most frequent in the first 2-3 years and then becomes less frequent.

9. Living with UESL

  • Ask for a named key worker or specialist nurse
  • Report fever immediately during chemotherapy
  • Avoid contact sports while the tumour is in place, because of rupture risk
  • Keep up nutrition; a dietitian can help if appetite is poor
  • Use school and psychology support to help your child return to normal life
  • Keep a treatment summary with chemotherapy doses for future doctors

10. Frequently asked questions

Question Answer
Is UESL the same as hepatoblastoma? No. It is a different liver cancer that affects older children and has normal AFP
Is it caused by liver disease? No. It is not linked to hepatitis or cirrhosis
Is it inherited? Usually not
Can the liver regrow after surgery? Yes. The liver regenerates well after partial removal
Will my child need a transplant? Only if the tumour cannot be removed by standard surgery
Does my child need radiotherapy? Usually not; it is reserved for tumour left behind or relapse
Can my child go back to school? Often yes between treatments, with advice on infections such as chickenpox and measles
Can adults get it? Yes, but rarely, and outcomes are usually less good

11. Questions to ask your care team

  • Can the tumour be completely removed, and when?
  • Will my child have chemotherapy before or after surgery?
  • Is a liver transplant a possibility?
  • What side effects should we expect?
  • How often will follow-up scans be needed?
  • Is my child eligible for a clinical trial?

Resources

  1. Bisogno, G. et al. (2002) ‘Undifferentiated sarcoma of the liver in childhood: a curable disease’, Cancer, 94(1), pp. 252-257.
  2. Guerin, F. et al. (2023) ‘Outcome of patients with undifferentiated embryonal sarcoma of the liver treated according to European soft tissue sarcoma protocols’, Pediatric Blood and Cancer, 70(7), e30374.
  3. Mathews, J. et al. (2013) ‘Characterization of translocations in mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver’, Experimental and Molecular Pathology, 95(3), pp. 319-324.
  4. Putra, J. and Ornvold, K. (2015) ‘Undifferentiated embryonal sarcoma of the liver: a concise review’, Archives of Pathology and Laboratory Medicine, 139(2), pp. 269-273.
  5. Shi, Y. et al. (2017) ‘Characteristics and outcomes in children with undifferentiated embryonal sarcoma of the liver: a report from the National Cancer Database’, Pediatric Blood and Cancer, 64(4), e26272.
  6. Stocker, J.T. and Ishak, K.G. (1978) ‘Undifferentiated (embryonal) sarcoma of the liver: report of 31 cases’, Cancer, 42(1), pp. 336-348.
  7. Techavichit, P. et al. (2016) ‘Undifferentiated embryonal sarcoma of the liver (UESL): a single-center experience and review of the literature’, Journal of Pediatric Hematology/Oncology, 38(4), pp. 261-268.
  8. Walther, A. et al. (2014) ‘Multimodal therapy including liver transplantation for hepatic undifferentiated embryonal sarcoma’, Liver Transplantation, 20(2), pp. 191-199.
  9. Ziogas, I.A. et al. (2021) ‘Undifferentiated embryonal sarcoma of the liver in children versus adults: a National Cancer Database analysis’, Cancers, 13(12), 2918.
  10. National Cancer Institute (2026) Childhood Liver Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/liver/hp/child-liver-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.